Editas Medicine, Inc. (NASDAQ:EDIT) Stock Has Average Price Target of $5.80

Editas Medicine, Inc. (NASDAQ:EDIT) has earned a consensus rating of “Moderate Buy” from the seven research firms that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation and six have assigned a buy recommendation to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $5.83.

A number of research firms have recently commented on EDIT. Weiss Ratings raised Editas Medicine from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Wells Fargo & Company upgraded Editas Medicine from an “equal weight” rating to an “overweight” rating and boosted their price objective for the company from $4.00 to $6.00 in a research report on Thursday. LADENBURG THALM/SH SH started coverage on Editas Medicine in a research report on Tuesday, August 18th. They issued a “buy” rating and a $6.00 price objective for the company. Wall Street Zen raised Editas Medicine from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. Finally, Guggenheim upgraded Editas Medicine from a “neutral” rating to a “buy” rating and set a $5.00 target price on the stock in a research note on Wednesday, September 23rd.

Institutional Investors Weigh In On Editas Medicine

Several large investors have recently made changes to their positions in EDIT. Legal & General Group Plc acquired a new stake in Editas Medicine in the 2nd quarter valued at about $31,000. Pallas Capital Advisors LLC acquired a new position in Editas Medicine in the 2nd quarter valued at $38,000. Abel Hall LLC acquired a new position in shares of Editas Medicine in the first quarter valued at about $36,000. Callan Family Office LLC acquired a new stake in Editas Medicine in the 2nd quarter worth about $47,000. Finally, Strategic Advisory Partners LLC bought a new stake in Editas Medicine in the 2nd quarter valued at about $49,000. Institutional investors and hedge funds own 71.90% of the company’s stock.

Editas Medicine Stock Performance

NASDAQ:EDIT opened at $2.90 on Monday. The firm has a market capitalization of $445.38 million, a price-to-earnings ratio of -3.87 and a beta of 2.00. The business’s 50-day moving average price is $2.86 and its two-hundred day moving average price is $2.89. Editas Medicine has a 1-year low of $1.66 and a 1-year high of $4.33.

Editas Medicine (NASDAQ:EDIT) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.12. Editas Medicine had a negative net margin of 157.32% and a negative return on equity of 196.63%. The business had revenue of $11.89 million for the quarter, compared to analyst estimates of $2.85 million. Sell-side analysts predict that Editas Medicine will post -0.80 earnings per share for the current year.

Editas Medicine News Roundup

Here are the key news stories impacting Editas Medicine this week:

• Positive Sentiment: EDIT-401 cleared to enter human trials: Australian regulators approved initiation of the Phase 1/2 Strive trial in patients with heterozygous familial hypercholesterolemia who need additional LDL-cholesterol reduction. Editas expects to begin dosing this year and report initial safety and tolerability data in the first quarter of 2027. Editas Medicine Receives Approval to Initiate First-In-Human Clinical Trial of EDIT-401
• Positive Sentiment: Promising preclinical data support the program: In non-human primate studies, EDIT-401 reportedly reduced LDL cholesterol and other harmful blood fats by approximately 90%, while additional data are expected at the American Heart Association Scientific Sessions. These results could strengthen the potential value of a one-time gene-editing treatment, though they do not guarantee success in humans. Editas Medicine Gets Clearance for First Human Trial of Gene-Editing Drug
• Positive Sentiment: Wells Fargo upgraded Editas to Overweight from Equal Weight and raised its price target to $6 from $4. The new target implies substantial upside from the recent trading level and reflects increased optimism about EDIT-401’s potential and the company’s prospects into 2027. Wells Fargo Upgrades Editas Medicine to Overweight
• Neutral Sentiment: Short-interest data appear inconsistent: The report lists short interest at zero shares and a zero-day days-to-cover ratio despite describing a large increase. This likely reflects a data or reporting anomaly and provides little reliable information about current trading sentiment.
• Negative Sentiment: Clinical and financial risks remain significant: EDIT-401 is entering its first human study, so safety, durability and cholesterol-lowering performance are unproven in patients. Editas also remains loss-making, making future financing needs and clinical setbacks important risks for shareholders.

Editas Medicine Company Profile

Editas Medicine, Inc is a biotechnology company focused on developing genomic medicines that use CRISPR-based gene-editing technologies to treat diseases caused by genetic abnormalities. The company’s research programs are designed to modify or correct disease-associated genes in patients’ cells, with the goal of developing potentially durable treatments.

Its lead investigational program is reni-cel, formerly known as EDIT-301, an ex vivo CRISPR gene-editing therapy being studied for sickle cell disease and transfusion-dependent beta thalassemia.